11 February 2026
4basebio PLC
(“4basebio” or the “Company”)
Director Dealings
Cambridge, UK,
11 February 2026
–
4basebio PLC
(AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 10 February 2026 it was informed that certain Non-executive Directors of the Company made the following purchases in ordinary shares in the capital of the Company through the market.
Further details are set out in the Notification of Dealing Form below.
|
|
|
|
|
|
|
Dr. Heikki Lanckriet |
3,000 |
575.82 |
1,122,688 |
7.23% |
|
Mr Hansjörg Plaggemars* |
1,000 |
585.00 |
7,667† |
0.05%† |
|
|
|
|
|
|
|
|
||||
The 3,000 and 1,000 additional shares purchased represent approximately 0.02 per cent. and 0.01 per cent. of the Company’s issued share capital, respectively.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
|
|
+44 (0)12 2396 7943 |
|
Dr Amy Walker, CEO |
|
|
|
|
|
|
+44 (0)20 7213 0880 |
|
Jo Turner / Sandy Jamieson / Ed Downes |
|
|
|
|
|
|
+44 (0)20 7220 0500 |
|
Geoff Nash / Nigel Birks |
|
|
|
|
|
|
+44 (0)20 7653 4000 |
|
Kathryn Deegan / Matthew Coakes
Mary-Jane Elliott / Jessica Hodgson |
+44 (0)203 707 5700 |
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio.
Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
|
||||||||||
|
a) |
Name
|
1)
2) |
|||||||||
|
|
|
||||||||||
|
a) |
Position/Status
|
1)
2)
|
|||||||||
|
b) |
Initial notification/ Amendment
|
Initial notification
|
|||||||||
|
|
|
||||||||||
|
a) |
Name
|
4basebio plc |
|||||||||
|
b) |
LEI
|
213800E2DX9EAIUNCB30 |
|||||||||
|
|
|
||||||||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares ISIN: GB00BMCLYF79 |
|||||||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares
|
|||||||||
|
c) |
Price(s) and volume(s)
|
|
|||||||||
|
d) |
Aggregated information
–
–
|
1)
2)
1)
2)
|
|||||||||
|
e) |
Date of transaction
|
10 February 2026 |
|||||||||
|
f) |
Place of transaction
|
London Stock Exchange |
|||||||||
